Personalis, Inc.

https://www.personalis.com

Personalis, Inc. is a genomics company specializing in advanced genomics for precision oncology. Founded in 2011 and incorporated in Delaware, the company's core business revolves around next-generation sequencing (NGS) technologies and molecular profiling platforms. Its mission is to transform the active management of cancer through breakthrough personalized testing, aiming to guide patient care from biopsy throughout their treatment journey. The company's headquarters are located in Fremont, California.

Personalis offers a suite of key products and services designed to provide comprehensive molecular data. These include NeXT Personal, a tumor-informed liquid biopsy test for detecting minimal residual disease (MRD), monitoring therapy response, and tracking recurrence in solid tumor cancers. The ImmunoID NeXT platform is a tissue-based service that combines whole exome and whole transcriptome sequencing with advanced analytics to offer a multi-dimensional view of tumors. Additionally, NeXT Dx provides tumor profiling for therapy selection and clinical trial matching, while the Real-Time Variant Tracker extends NeXT Personal's capabilities to monitor therapy resistance mutations. The company's services, including sequencing and data analysis, cater to pharmaceutical companies, diagnostic firms, research institutions, and cancer patients.

In terms of leadership and recent developments, Chris Hall serves as the Chief Executive Officer, appointed in March 2023. Richard Chen was promoted to President in March 2026, while continuing his role as Chief Medical Officer. Personalis has recently secured significant milestones, including Medicare coverage for its NeXT Personal test for lung cancer surveillance in February 2026 and for breast cancer recurrence surveillance in late 2025. The company reported a substantial increase in clinical test volume in 2025 and projects continued growth for 2026, driven by these coverage expansions. Personalis operates within the competitive and rapidly expanding liquid biopsy market, positioning itself as a leader in ultrasensitive MRD detection and comprehensive genomic profiling.

Latest updates

Personalis Data Shows ctDNA Monitoring Improves Colorectal Cancer Outcomes

Event summary

  • Personalis presented data at the AACR Annual Meeting demonstrating the clinical impact of its NeXT Personal ultrasensitive ctDNA assay.
  • The NEOPRISM-CRC trial showed 100% sensitivity for disease at baseline and correlated ctDNA levels with pathological complete response in neoadjuvant colorectal cancer treatment.
  • A real-world analysis of nearly 25,000 plasma samples revealed 39% of MRD detections occurred below 100 PPM, highlighting the assay's ultrasensitivity.
  • Personalis debuted a new Real-Time Variant Tracker feature for its NeXT Personal MRD test, identifying resistance mutations in 38% of MRD-positive patients.

The big picture

Personalis's data reinforces the growing trend towards personalized cancer treatment guided by molecular biomarkers. The ability to predict treatment response and track resistance with high sensitivity offers a significant clinical advantage, but widespread adoption hinges on demonstrating cost-effectiveness and securing reimbursement. The Real-Time Variant Tracker feature represents a move towards more comprehensive monitoring, potentially creating a stickier product offering.

What we're watching

Clinical Adoption
The pace at which clinicians integrate ctDNA monitoring into standard neoadjuvant colorectal cancer treatment protocols will determine the assay’s revenue potential.
Reimbursement
Whether payers will adopt coverage for ultrasensitive ctDNA monitoring, particularly given the cost implications, remains a critical factor for Personalis's long-term growth.
Competitive Landscape
The emergence of competing ultrasensitive ctDNA assays and the potential for consolidation within the precision oncology diagnostics space could impact Personalis's market share.

Personalis Unveils Therapy Resistance Tracking in ctDNA Assay

Event summary

  • Personalis will present data at the AACR Annual Meeting (April 17-22, 2026) focused on its NeXT Personal ultrasensitive ctDNA assay.
  • A key feature highlighted is the 'Real-Time Variant Tracker,' a new MRD test option designed to longitudinally track therapy resistance mutations.
  • The AACR presentations include an oral podium presentation on colorectal cancer data and three poster presentations.
  • One poster focuses on analytical validation and real-world data for the Real-Time Variant Tracker, while another demonstrates detection levels below 100 ppm and 10 ppm across various cancers.

The big picture

Personalis's focus on ultrasensitive ctDNA analysis and therapy resistance tracking reflects a broader trend towards personalized oncology and earlier cancer detection. The introduction of the Real-Time Variant Tracker positions Personalis to capture a larger share of the growing MRD testing market, which is increasingly important for guiding treatment decisions and monitoring disease recurrence. However, the company's success hinges on demonstrating clinical utility and securing favorable reimbursement policies.

What we're watching

Clinical Adoption
The pace at which oncologists integrate the Real-Time Variant Tracker into clinical workflows will determine its commercial success and impact on patient management.
Competitive Landscape
How competitors respond to Personalis’s introduction of Real-Time Variant Tracker, particularly in terms of developing similar capabilities, will shape the future of MRD testing.
Reimbursement
Whether payers will reimburse for the Real-Time Variant Tracker, given its complexity and potential to influence treatment decisions, will be crucial for Personalis’s revenue growth.

Personalis to Present at Needham Conference Amidst MRD Testing Growth

Event summary

  • Personalis management will participate in the 25th Annual Needham Virtual Conference on April 15, 2026.
  • Personalis focuses on advanced genomics for precision oncology, particularly minimal residual disease (MRD) detection.
  • The company's assays combine tumor and normal profiling with proprietary algorithms.
  • Personalis aims to guide cancer care throughout the patient journey, enabling targeted therapies and biomarker strategy.

The big picture

The announcement highlights Personalis' ongoing efforts to establish itself as a leader in precision oncology, a market increasingly focused on early cancer detection and personalized treatment. The company's focus on MRD testing aligns with a broader trend towards more proactive and data-driven cancer management. Participation in the Needham conference signals a continued emphasis on investor relations and market visibility as the company seeks to scale its operations and expand its commercial reach.

What we're watching

Market Adoption
The conference presentation will likely reveal early adoption rates of Personalis' MRD testing services, which will be a key indicator of revenue generation and market penetration.
Competitive Landscape
The Needham conference provides an opportunity to gauge investor sentiment regarding Personalis' competitive positioning against other players in the rapidly evolving MRD testing space.
Clinical Validation
Continued clinical validation of Personalis' assays and their impact on patient outcomes will be crucial for securing reimbursement and expanding clinical utility.

Personalis Elevates Chen to President Amid MRD Market Shift

Event summary

  • Personalis has promoted Richard Chen, M.D., M.S. to President, while retaining his role as Chief Medical Officer (CMO).
  • The move signals a strategic shift for Personalis, transitioning from a research and development focus to a market leadership position in Minimal Residual Disease (MRD) testing.
  • Chen spearheaded the development of the NeXT Personal® platform, a key driver of Personalis' ultrasensitive MRD testing capabilities.
  • The promotion aims to integrate R&D, biopharma services, reimbursement, quality systems, and medical affairs to accelerate revenue growth.

The big picture

Personalis's move reflects a broader trend in precision oncology towards earlier cancer detection and intervention. The company's focus on MRD testing, a rapidly growing segment, positions it to capitalize on the increasing demand for personalized cancer therapies. However, transitioning from a research-driven model to a commercial leader requires a significant shift in operational focus and execution capabilities, which carries inherent risks.

What we're watching

Execution Risk
The success of this transition hinges on Chen’s ability to effectively integrate disparate departments and translate technological advancements into tangible revenue growth, a historically challenging feat for R&D-heavy firms.
Adoption Rate
The pace at which Personalis can secure adoption of its ultrasensitive MRD testing within pharmaceutical drug trials and physician workflows will dictate the speed of its market leadership claim.
Competitive Landscape
How competitors respond to Personalis’s aggressive positioning in the MRD market, particularly regarding pricing and alternative testing methodologies, will shape the long-term viability of its market dominance.

Personalis Study Highlights Ultrasensitive ctDNA Testing for Breast Cancer Prognosis

Event summary

  • Personalis published the PREDICT-DNA study in the Journal of Clinical Oncology, demonstrating the utility of its NeXT Personal assay for monitoring breast cancer treatment response.
  • The study followed 227 patients with Triple-Negative (TNBC) and HER2+ breast cancer across 24 US cancer centers.
  • The study found that 55% of detectable ctDNA post-neoadjuvant therapy occurred below 100 parts per million, highlighting the importance of ultrasensitive testing.
  • ctDNA status post-neoadjuvant therapy was a stronger predictor of recurrence than traditional metrics like nodal status and pathologic complete response (pCR).

The big picture

The PREDICT-DNA study validates the growing trend towards personalized oncology and the use of liquid biopsies for treatment monitoring. The ability to detect minimal residual disease (MRD) with greater sensitivity offers the potential to improve patient outcomes and guide treatment decisions, but also introduces challenges related to cost, reimbursement, and clinical adoption. This finding could accelerate the shift away from traditional, less precise, diagnostic methods in oncology.

What we're watching

Reimbursement
The success of Personalis’ efforts to expand reimbursement coverage for NeXT Personal will be critical for widespread adoption and revenue growth, particularly given the assay’s higher cost relative to standard approaches.
Clinical Adoption
The pace at which oncology centers integrate ultrasensitive ctDNA testing into standard clinical workflows will determine the assay’s impact on patient outcomes and Personalis’ market penetration.
Competitive Landscape
How competitors respond to Personalis’ findings and develop competing ultrasensitive ctDNA assays will shape the long-term viability of the market and Personalis’ competitive advantage.

Personalis Secures Medicare Coverage, Volume Surges Amidst Revenue Decline

Event summary

  • Personalis reported a 14.5% revenue decrease YoY, from $84.6 million to $69.6 million for the full year 2025.
  • Clinical test volume increased nearly 400% YoY, reaching 16,233 tests in 2025, and 41% sequentially in Q4 2025.
  • The company secured Medicare coverage for breast cancer recurrence surveillance in Q4 2025 and lung cancer in Q1 2026.
  • Personalis ended 2025 with $240 million in cash, funded in part by $109 million from an ATM offering at an average price of $8.43 per share.

The big picture

Personalis is attempting to capitalize on the growing demand for advanced genomic testing in oncology, particularly in the area of minimal residual disease (MRD) detection. The Medicare coverage approvals represent a significant opportunity, but the company's revenue decline and reliance on an ATM offering suggest challenges in balancing growth with profitability. The company’s strategy of prioritizing volume adoption ahead of full reimbursement coverage is a high-risk, high-reward approach that could either establish market leadership or exacerbate financial pressures.

What we're watching

Reimbursement Impact
The actual uptake of Personalis’ services following Medicare coverage approval will be critical, and the timing of revenue recognition remains uncertain given the stated gross margin strategy.
Volume Sustainability
Whether Personalis can maintain the accelerated clinical test volume growth rate achieved in 2025, particularly as reimbursement matures, warrants close monitoring.
Cash Burn
The company’s projected $100 million cash usage in 2026, driven by commercial investments, will test the resilience of its balance sheet and necessitate disciplined spending.

Medicare Coverage Boosts Personalis' Lung Cancer Test, Validates MRD Approach

Event summary

  • Personalis received Medicare coverage for its NeXT Personal molecular residual disease (MRD) test for lung cancer surveillance.
  • The coverage is supported by clinical data from the TRACERx consortium, published in Cell.
  • NeXT Personal uses whole-genome sequencing to detect trace amounts of circulating tumor DNA (ctDNA).
  • The test targets patients with Stage I to III non-small cell lung cancer (NSCLC), a market of approximately 230,000 new cases annually.

The big picture

This Medicare coverage represents a significant validation of Personalis’ technology and a potential revenue driver, but also highlights the increasing focus on early cancer detection and personalized treatment approaches. The reliance on TRACERx data underscores the importance of collaborative research in securing regulatory and reimbursement pathways for novel diagnostics. While the lung cancer market is substantial, the success of NeXT Personal hinges on demonstrating tangible clinical benefit and navigating the complexities of healthcare reimbursement.

What we're watching

Adoption Rate
The speed at which oncologists and hospitals integrate NeXT Personal into standard lung cancer surveillance protocols will determine the test’s revenue impact, and is dependent on clinician comfort and reimbursement clarity.
Competitive Landscape
The emergence of competing ultrasensitive MRD tests, or alternative surveillance methods, could erode Personalis’ market share and pricing power, especially if they offer a more cost-effective solution.
Clinical Validation
Further clinical data demonstrating the impact of NeXT Personal on patient outcomes (e.g., reduced recurrence rates, improved survival) will be crucial for sustaining Medicare coverage and expanding indications.

Personalis Data Suggests Earlier Immunotherapy Response Detection

Event summary

  • Personalis published a study in *npj Precision Oncology* demonstrating the utility of its NeXT Personal assay for monitoring immunotherapy response.
  • The study, involving 39 patients with advanced solid tumors across nine cancer types, showed molecular response detectable as early as 23 days after immunotherapy initiation.
  • NeXT Personal identified molecular progression up to 161 days (over five months) before imaging in patients whose disease progressed.
  • Patients achieving molecular complete response (ctDNA clearance) had seven times higher overall survival than those who did not.

The big picture

The success of immunotherapy is highly variable, and the ability to predict response early is a significant unmet need. Personalis’s data suggests that its ultrasensitive ctDNA assay, NeXT Personal, could provide valuable insights for clinicians, potentially improving patient outcomes and optimizing treatment strategies. However, the adoption of such advanced diagnostics hinges on clinical validation, reimbursement, and competition within the rapidly evolving precision oncology space.

What we're watching

Clinical Adoption
The pace at which oncologists integrate ultrasensitive ctDNA monitoring into standard immunotherapy treatment protocols will determine NeXT Personal’s revenue trajectory.
Reimbursement
Whether payers will adopt NeXT Personal as a standard of care, given the assay's cost and the potential for earlier intervention, remains a critical factor for Personalis’s long-term profitability.
Competitive Landscape
The emergence of competing ultrasensitive ctDNA assays and the potential for larger diagnostic players to enter the market could erode Personalis’s market share.

Personalis to Present at BTIG MedTech Conference Amidst MRD Testing Growth

Event summary

  • Personalis management will attend the BTIG MedTech Conference on February 11, 2026.
  • The conference is hosted at the Cliff Lodge in Snowbird, Utah.
  • Personalis focuses on advanced genomics for precision oncology, particularly minimal residual disease (MRD) detection.
  • The company’s assays combine tumor and normal profiling with proprietary algorithms.

The big picture

Personalis' participation in the BTIG conference underscores the growing importance of minimal residual disease (MRD) testing in cancer management. The precision oncology market is experiencing rapid growth, driven by advancements in genomic sequencing and a shift towards personalized therapies. The conference provides a platform for Personalis to showcase its technology and engage with investors and potential partners, but also exposes them to scrutiny regarding their competitive positioning and financial outlook.

What we're watching

Market Adoption
The conference presentation will reveal the extent to which Personalis’ MRD testing is gaining traction with oncologists and impacting clinical workflows, given the increasing emphasis on early cancer detection.
Competitive Landscape
How Personalis differentiates its approach from competitors offering similar genomic profiling services will be crucial, especially as the market for MRD testing becomes more crowded.
Financial Performance
The conference provides an opportunity to gauge investor sentiment and expectations regarding Personalis’ revenue growth and path to profitability, particularly in light of ongoing R&D investments.

Personalis Adds Mutation Tracking to MRD Test, Targets Therapy Optimization

Event summary

  • Personalis launched Real-Time Variant Tracker, an add-on to its NeXT Personal molecular residual disease (MRD) test.
  • The new feature provides clinicians with reporting on resistance and therapeutically targetable mutations, including ESR1.
  • Real-Time Variant Tracker is initially available through an Early Access Program (EAP) for clinical and academic leaders.
  • The feature is also available to Personalis’ biopharma partners.

The big picture

Personalis is attempting to differentiate its MRD testing offering by moving beyond simple ctDNA detection to provide actionable insights on emerging resistance mechanisms. This shift reflects a broader trend towards personalized cancer treatment and the increasing use of genomic data to guide therapeutic decisions. While the MRD market is growing, the ability to deliver clinically relevant and actionable data will be key to securing market share and driving long-term value.

What we're watching

Adoption Rate
The success of Real-Time Variant Tracker hinges on the adoption rate within the Early Access Program and subsequent broader clinical integration, which will dictate near-term revenue impact.
Clinical Validation
How the clinical utility and impact of the mutation tracking feature are validated through real-world data will be crucial for long-term reimbursement and market acceptance.
Competitive Response
Other players in the MRD testing space will likely respond to Personalis’ innovation, potentially accelerating the development of similar capabilities and intensifying competition.

Personalis Revenue Slides as Clinical Volume Surges

Event summary

  • Personalis anticipates full-year 2025 revenue of $69.0–$70.0 million, a decrease from $84.6 million in 2024.
  • Clinical test volume increased nearly 400% year-over-year, reaching approximately 16,233 tests.
  • The company secured Medicare coverage for cancer recurrence surveillance in breast cancer patients.
  • Personalis ended 2025 with $240 million in cash, cash equivalents, and short-term investments, boosted by $109 million from an ATM offering.

The big picture

Personalis' preliminary results highlight a complex picture: while clinical volume is exploding thanks to the NeXT Personal platform and recent reimbursement approval, overall revenue has declined, suggesting pricing pressures or shifts in revenue mix. The company’s aggressive growth strategy, coupled with a substantial cash reserve, positions it to expand its market footprint, but the revenue shortfall raises questions about long-term financial sustainability and the efficiency of its enterprise sales and population sequencing initiatives.

What we're watching

Reimbursement
The success of Personalis' breast cancer surveillance coverage will dictate the speed of adoption and revenue generation in the MRD space, and whether similar approvals can be secured for other cancer types.
Growth Sustainability
Whether Personalis can maintain its accelerated clinical volume growth rate (nearly 400% YoY) into 2026, given the relatively small base and potential for market saturation.
Financial Performance
The company's ability to return to revenue growth in 2026, given the 2025 decline, will depend on the conversion of clinical volume into sustainable revenue streams and the impact of the ATM offering.
CID: 583